β-Blockers for chronic heart failure: From prejudice to enlightenment

Journal of Cardiovascular Pharmacology

Volumn 32, Issue SUPPL. 1, 1998, Pages

  Cleland, John G F ^a   McGowan, James ^a   Cowburn, Peter J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Blockers; Congestive heart failure; Left ventricular function

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CARVEDILOL; DILTIAZEM; NEBIVOLOL; PROPRANOLOL; VERAPAMIL;

ASTHMA; BRADYCARDIA; CONFERENCE PAPER; DIARRHEA; DRUG EFFECT; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; PRIORITY JOURNAL; SODIUM EXCRETION; TREATMENT CONTRAINDICATION; VERTIGO;

ADRENERGIC BETA-ANTAGONISTS; ASTHMA; EXERCISE TEST; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION; QUALITY OF LIFE; VENTRICULAR DYSFUNCTION;

EID: 0031690592     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199800003-00009     Document Type: Conference Paper

References (45)

1. Epstein SE, Braunwald E. The effect of beta-adrenergic blockade on patterns of urinary sodium excretion. Ann Intern Med 1966;65: 20-7.
2. Taylor RR, Johnston CL, Jose AD. Reversal of digitalis intoxication by beta-adrenergic blockade with pronethalol. N Eng J Med 1964;271:877-82.
3. Stock JPP, Dale N. Beta-adrenergic receptor blockade in cardiac arrhythmias. BMJ 1963;1230-3.
4. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338:1281-5.
5. Wikstrand J, Berglund G. Antihypertensive treatment with beta-blockers in patients aged over 65. BMJ 1982;285:850.
6. Snow PJD. Effect of propranolol in myocardial infarction. Lancet 1965;2:551-3.
7. Von der Lippe g, Hansen HS, Lund-Johansen P, Nordrehaug JE, et al., and the Norwegian Multicentre Study Group. Timolol induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-7.
8. β-Blocker Heart Attack Trial Research Group. A randomised trial by propranolol in patients with acute myocardial infarction. JAMA 1983;250:2814-9.
9. β-Blocker Heart Attack Trial Research Group. A randomised trial of propranolol in patients with acute myocardial infarction. JAMA 1982;247:1707-14.
10. Hjalmarson A, Herlitz J, Malek I, et al. Effect on mortality of metoprolol in acute myocardial infarction. Lancet 1981;823-7.
11. Kober L, Torp Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-6.
12. Kober L, Torp Pedersen C. Clinical characteristics and mortality of patients screened for entry into the Trandolapril Cardiac Evaluation (TRACE) study. Am J Cardiol 1995;76:1-5.
13. Gundersen T. Influence of heart size on mortality and reinfarction in patients treated with timolol after myocardial infarction. Br Heart J 1983;50:135-9.
14. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986;73:503-10.
15. Herlitz J. Effect of metoprolol among patients with suspected acute myocardial infarction and left ventricular dysfunction [Abstract]. Eur Heart J 1996;17(suppl):514.
16. Herlitz J, Hjalmarson A, Holmberg S, et al. Development of congestive heart failure after treatment with metoprolol in acute myocardial infarction. Br Heart J 1984;51:539-44.
17. Cleland JGF, Bristow M, Erdmann E, Remme WJ, Swedberg K, Waggstein F. Beta-blocking agents in heart failure. Should they be used and how? Eur Heart J 1996;17:1629-39.
18. Australia-New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375-80.
19. Packer M, Bristow MR, Cohn JN, et al., for the US Carvedilol Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334: 1349-55.
20. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342: 1441-6.
21. Lechat P, Jaillon P, Fontaine ML, et al. A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-73.
22. Packer M, Colucci WS, Sackner Bernstein JD, et al., for the PRECISE study group. Double-blind, placebo controlled study of the effects of carvedilol in patients with moderate to severe heart failure. Circulation 1996;94:2793-9.
23. Colucci WS, Packer M, Bristow MR, et al., for the US Carvedilol Heart Failure Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800-6.
24. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomised study. J Am Coll Cardiol 1995;25:1225-31.
25. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator B-blocker, in patients with congestive heart failure due to ischaemic heart disease. Circulation 1995;92:212-8.
26. Narang R, Swedberg K, Cleland JGF. What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effects of ACE inhibitors on exercise capacity. Eur Heart J 1996;17:120-34.
27. Krum H, Sackner Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92: 1499-1506.
28. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1687.
29. Bristow MR, Gilbert EM, Abraham WT, et al., for the MOCHA Investigators: Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-16.
30. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995;25:1154-61.
31. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N, on behalf of the Australia-New Zealand heart failure research collaborative group: Left ventricular remodelling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 1997;29:1060-6.
32. Nicholas G, Oakley C, Pouleur H, et al. Xamoterol in severe heart failure. Lancet 1990;336:1-6.
33. Yusuf S. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
34. Cleland JGF, Erdmann E, Ferrari R, et al. Guidelines for the diagnosis of heart failure. Eur Heart J 1995;16:741-51.
35. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71.
36. Cleland JGF, Ray SG, McMurray JJV: Overview of post infarction trials. In: Cleland JGF, ed. Prevention strategies after myocardial infarction. London: Science Press, 1994:37-73.
37. Cleland JGF, JJF McMurray, PJ Cowburn. Heart failure: a systematic approach for clinical practice. London: Science Press, 1997:1-123.
38. Jonas M, Reicherreis H, Boyko V, et al. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Am J Cardiol 1996;77:1273-7.
39. Choudhri AH, Cleland JGF, Rowlands PC, Tran TL, McCarty M, Al Kutoubi MAO. Unsuspected renal artery stenosis in peripheral vascular disease. BMJ 1990;301:1197-8.
40. Packer M, Colucci WS, Sackner-Bernstein J, et al. Prospective randomized evaluation of carvedilol on symptons and exercise tolerance in chronic heart failure: results of the PRECISE Trial. Circulation 1995;92(suppl I):1-143.
41. Bristow MR, Gilbert EM, Abraham WT, et al. Multicenter oral carvedilol heart failure assessment (MOCHA): a six-month dose-response evaluation in class II-IV patients [Abstract]. Circulation 1995;92(suppl 1):1-142.
42. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild heart failure [Abstract]. Circulation 1995;92(suppl I):1-395.
43. Sackner-Bernstein J, Krum H, Goldsmith RL, et al. Should worsening heart failure early after initiation of beta-blocker therapy for chronic heart failure preclude long-term treatment? [Abstract] Circulation 1995;92(suppl I):1-395.
44. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996;14:489-94.
45. Pollare T, Lithell HO, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double-blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989;298:1152-7.